Forward lookingstatements New York Yankees include but are not limited

Forward-lookingstatements studies aj burnett include, but autographed baseball uncovers are not limited to, statements that express ourintentions, beliefs, expectations, strategies, predictions or any otherstatements relating to our future activities or other future events orconditions. CapStone Investments is a member of the FinancialIndustry Regulatory Authority (FINRA), the Securities Investor ProtectionCorporation (SIPC) and the Municipal Securities Rulemaking Board (MSRB).CapStone Institutional Services (CapStone) is a division of CapStoneInvestments. The webcastcan also be accessed at http:// online.About CapStone InvestmentsCapStone Investments is a full service investment firm, servicing a largeinstitutional account base. The Company's second solution, Visual3Dx(TM), will generate 3Dinformation from the heart using standard 12-lead ECG data. It is expected toprovide clinicians additional information on the extent and location of damageto the heart caused by a myocardial infarction and to improve the speed andaccuracy of diagnosis.Management will also be available for one-on-one meetings throughout the day.Interested parties may schedule meetings through their CapStone Investments'representative.The presentation will be webcast live on the Company's "News and Events" pageat The webcast will be archived for 90 days.

NewCardio's lead product is QTinno(TM), asoftware suite that provides an automated, comprehensive analysis of QTintervals and other ECG-based cardiac safety for the pharmaceutical industryand drug regulators alex rodriguez . The Company believes that its QTinno(TM), software-based,analytical technology is the industry's first solution for the reliableautomated analysis of ECGs used to determine cardiac toxicity during drugdevelopment autographed bats . The presentation is intended to provide institutional investors and researchanalysts with a broad overview of the Company's innovative 3D ECG platformtechnology and the applications for this technology to dramatically improveaccuracy and significantly increase the diagnostic value of the standard12-lead electrocardiogram (ECG) baseball simulation . CDT on July 30, 2009SANTA CLARA, Calif., July 23 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTCBulletin Board: NWCI) a cardiac diagnostic and services company, todayannounced that Richard Brounstein, the Company's Executive Vice President andChief Financial Officer, will present at CapStone Investments' Third AnnualSmall-Cap Investor Conference, to be held July 29-30, 2009, in Milwaukee atthe Hyatt Regency Hotel NewCardio is scheduled to present at 12:30 p.m CDTon July 30, 2009 baseball tickets . NewCardio to Present at CapStone's Third Annual Small-Cap Investor ConferenceJuly 30Scheduled to present at 12:30 p.m. Clients rely on this analysis and data to make informeddecisions Please visit Decision Resources, Inc. at company, brand or product names contained in this document may betrademarks or registered trademarks of their respective holders.For more information, contact:Gisselle Morales Elizabeth MarshallDecision Resources Decision Resources, Inc.781-296-2691 SOURCEDecision ResourcesGisselle Morales of Decision Resources, +1-781-296-2691,; or Elizabeth Marshall of Decision Resources, Inc.,+1-781-296-2563, .

is a cohesive portfolio of companies that offersbest-in-class, high-value information and insights on important sectors of thehealthcare industry alex rodriguez bio . As Invega continues to experience increased uptake in earlylines of therapy, surveyed psychiatrists indicate that risperidone and Zyprexawill lose the most share autographed baseball . These data indicate that marketers of current andemerging atypical antipsychotics will need to position themselves againstInvega's growing use as an early-line agent autographed bats . However, surveyed psychiatristsexpect to substantially increase their first- and second-line prescriptionsfor the drug . Patient-flow analysis for Janssen's Invega shows that only three percent ofall users took the drug as a first-line agent. The majority ofsurveyed psychiatrists will switch patients from atypicals with unfavorablemetabolic side-effect profiles to those with more favorable profiles orincreasingly consider weight gain and metabolic side-effect profiles whenchoosing an antipsychotic in the first-line.By combining patient-level claims data with physician survey data, this reportcan be used to build patient-flow models and analyze the assumptions drivingthese models.